Eppendorf SE Presentation: The Power of Small-Scale Parallel Bioreactor Systems in Cell Therapy Development
Thursday, May 30, 2024 10:30 AM - 10:45 AM
Exhibit Hall - Theatre A
Global Showcase Presentation
The Power of Small-Scale Parallel Bioreactor Systems in Cell Therapy Development
Presenter:
• Vanja Misic PhD, Director, Process & Analytical Development, Morphocell Technologies Inc., CANADA
Efficient implementation of a Quality by Design (QbD) approach for the development of manufacturing processes of cell therapies requires the use of Design of Experiments (DoE) enabled studies.
However, for the development of processes in stirred tank reactors (STRs), efficient screening and subsequent optimization of multiple factors (i.e., process parameters and material attributes) simultaneously are usually not practical at production scales.
Therefore, scale-down models are needed to facilitate DoE studies, and the process knowledge and understanding gained from them must be translatable at the production scale. Accordingly, use of small-scale, parallel bioreactors that can independently monitor and control the same process parameters (temperature, pH, DO, P/V, etc.) as production scale bioreactors, is the most efficient way to develop an STR-based process for the manufacturing of cell therapies.
Session Objectives:
• Understanding the role and benefits of small-scale parallel bioreactors in cell therapy R&D.
• Insights into how these systems ensure a seamless scale-up process.
• Learning about advanced monitoring and control techniques for optimal cell culture conditions.
• Future perspectives on the impact of these technologies in the cell therapy sector.
Presenter:
• Vanja Misic PhD, Director, Process & Analytical Development, Morphocell Technologies Inc., CANADA
Efficient implementation of a Quality by Design (QbD) approach for the development of manufacturing processes of cell therapies requires the use of Design of Experiments (DoE) enabled studies.
However, for the development of processes in stirred tank reactors (STRs), efficient screening and subsequent optimization of multiple factors (i.e., process parameters and material attributes) simultaneously are usually not practical at production scales.
Therefore, scale-down models are needed to facilitate DoE studies, and the process knowledge and understanding gained from them must be translatable at the production scale. Accordingly, use of small-scale, parallel bioreactors that can independently monitor and control the same process parameters (temperature, pH, DO, P/V, etc.) as production scale bioreactors, is the most efficient way to develop an STR-based process for the manufacturing of cell therapies.
Session Objectives:
• Understanding the role and benefits of small-scale parallel bioreactors in cell therapy R&D.
• Insights into how these systems ensure a seamless scale-up process.
• Learning about advanced monitoring and control techniques for optimal cell culture conditions.
• Future perspectives on the impact of these technologies in the cell therapy sector.
SPONSORED BY:
